Correlation Between Vincerx Pharma and AN2 Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Vincerx Pharma and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vincerx Pharma and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vincerx Pharma and AN2 Therapeutics, you can compare the effects of market volatilities on Vincerx Pharma and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vincerx Pharma with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vincerx Pharma and AN2 Therapeutics.

Diversification Opportunities for Vincerx Pharma and AN2 Therapeutics

-0.21
  Correlation Coefficient

Very good diversification

The 3 months correlation between Vincerx and AN2 is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding Vincerx Pharma and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Vincerx Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vincerx Pharma are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Vincerx Pharma i.e., Vincerx Pharma and AN2 Therapeutics go up and down completely randomly.

Pair Corralation between Vincerx Pharma and AN2 Therapeutics

Given the investment horizon of 90 days Vincerx Pharma is expected to under-perform the AN2 Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Vincerx Pharma is 1.42 times less risky than AN2 Therapeutics. The stock trades about -0.36 of its potential returns per unit of risk. The AN2 Therapeutics is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  110.00  in AN2 Therapeutics on August 29, 2024 and sell it today you would earn a total of  29.00  from holding AN2 Therapeutics or generate 26.36% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy95.65%
ValuesDaily Returns

Vincerx Pharma  vs.  AN2 Therapeutics

 Performance 
       Timeline  
Vincerx Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Vincerx Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
AN2 Therapeutics 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in AN2 Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, AN2 Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Vincerx Pharma and AN2 Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Vincerx Pharma and AN2 Therapeutics

The main advantage of trading using opposite Vincerx Pharma and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vincerx Pharma position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.
The idea behind Vincerx Pharma and AN2 Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals